Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022

This report describes a recommendation for using a 4-month regimen for the treatment of drug-susceptible pulmonary tuberculosis.
Source: CDC Morbidity and Mortality Weekly Report - Category: American Health Tags: Healthy Living MMWR Morbidity & Mortality Weekly Report Tuberculosis (TB) Tuberculosis Vaccine (BCG) Source Type: news